This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
Nature Communications Open Access 28 October 2023
-
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
Leukemia Open Access 23 April 2020
-
Development of a protein-based system for transient epigenetic repression of immune checkpoint molecule and enhancement of antitumour activity of natural killer cells
British Journal of Cancer Open Access 21 January 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D et al. Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cells interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia 2015; 29:1441–1444.
Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M et al. Preliminary results of a phase I study of Nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 2014; 124: 291.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189–2199.
Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(−) compartment. Blood 2001; 98: 2817–2827.
Brown RD, Spencer A, Ho PJ, Kennedy N, Kabani K, Yang S et al. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leuk Lymphoma 2009; 50: 1860–1864.
Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J 2013; 3: e148.
Suen H, Joshua DE, Brown RD, Yang S, Barbaro PM, Ho PJ et al. Protective cytotoxic clonal T-cells in myeloma have the characteristics of telomere-independent senescence rather than an exhausted or anergic phenotype: Implications for immunotherapy. Blood 2014; 124: 3367.
Monteiro J, Batliwalla F, Ostrer H, Gregersen PK . Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 1996; 156: 3587–3590.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Suen, H., Brown, R., Yang, S. et al. The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study. Leukemia 29, 1621–1622 (2015). https://doi.org/10.1038/leu.2015.104
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.104
This article is cited by
-
Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
Nature Communications (2023)
-
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma
Leukemia (2020)
-
Development of a protein-based system for transient epigenetic repression of immune checkpoint molecule and enhancement of antitumour activity of natural killer cells
British Journal of Cancer (2020)
-
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Journal of Hematology & Oncology (2018)
-
The multi-faceted potential of CD38 antibody targeting in multiple myeloma
Cancer Immunology, Immunotherapy (2017)